OraSure Technologies (OSUR)
(Delayed Data from NSDQ)
$4.25 USD
+0.04 (0.95%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $4.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.25 USD
+0.04 (0.95%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $4.25 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 133.33% and 1.86%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q1 Earnings Meet Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 0% and 3.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 108.96% and 10.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 2.33% and 2.28%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Q4 Earnings Match Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
by Zacks Equity Research
Otter Tail, OraSure, BioMarin and Regeneron have been highlighted in this Screen of The Week article.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), OraSure (OSUR) and BioMarin Pharmaceutical (BMRN) are well-poised to gain.
After Golden Cross, OraSure Technologies (OSUR)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
OraSure Technologies (OSUR) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 285.71% and 19.36%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -16.67% and 32.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 131.25% and 21.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how OraSure Technologies (OSUR) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
OraSure (OSUR) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
OraSure (OSUR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Zacks.com featured highlights include OraSure Technologies, Compania de Minas Buenaventura SAA and Vipshop
by Zacks Equity Research
OraSure Technologies, Compania de Minas Buenaventura SAA and Vipshop are part of the Zacks Screen of the Week article.
3 Low-Beta Stocks to Buy to Combat the Volatile Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. OraSure Technologies (OSUR), Compa??ia de Minas (BVN) and Vipshop Holdings (VIPS) are poised to gain.
Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock
by Zacks Equity Research
OraSure (OSUR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 100% and 13.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 67.57% and 2.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -320.00% and 13.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate OraSure Technologies (OSUR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for OraSure Technologies (OSUR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to OraSure Technologies (OSUR) stock based on the movements in the options market lately.